课题基金 / 基金详情

DENDRITIC CELLS FOR INDUCTION OF ALLOGRAFT TOLERANCE

DENDRITIC CELLS FOR INDUCTION OF ALLOGRAFT TOLERANCE
用于诱导同种异体移植物耐受的树突状细胞
批准号:
6651990
负责人:
STEVEN R DUNCAN
金额:
$27.3万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-08-15 至 2004-07-31

项目摘要

项目成果

STEVEN R DUNCAN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the Applicant's Abstract): This proposal is designed to develop new methods using dendritic cells (DC) to induce allotolerance in a mouse model. The proposal is based on the observation that i.v. infused thymic DCs selectively home to thymus and induce alloantigenic tolerance as compared to splenic DCs that show impaired thymic homing capabilities and do not have the ability to induced tolerance. These data are corroborated by the ability of thymic DCs to selectively home in the thymus after adoptive transfer leading to tolerance. The overall goals of this proposal are to 1) understand the mechanism(s) of the tolerance induced by allogeneic DCs, 2) define the DC subpopulation with the highest tolerogenic capability, and 3) develop the technical methodologies designed to optimize the use of adoptive transfer of DCs to induce allotolerance. The focus of this proposal is to further develop methodologies that will render DC tolerogen therapies clinically feasible. In particular, they propose to fully delineate mechanisms of effects in this system, improve methods for identification and isolation of DC with therapeutic potential, increase the duration of tolerance, explore the phenotypes necessary for unique thymic homing, and develop in vitro techniques to propagate or immortalize these cells. In addition to basic implications, they propose that their findings may ultimately have significant clinical applications, with considerable practical advantages over other methods for intrathymic introduction of neo-antigens to obviate allograft rejection and other T-cell-mediated disease processes.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
CD28 down-regulation on CD4 T cells is a marker for graft dysfunction in lung transplant recipients.
CD4 T 细胞上的 CD28 下调是肺移植受者移植物功能障碍的标志。
DOI: 10.1164/rccm.200701-013oc
发表时间: 2008
期刊: American journal of respiratory and critical care medicine
影响因子: 24.7
作者: [Studer,SeanM, George,MPatricia, Zhu,Xuehai, Song,Yifang, Valentine,VincentG, Stoner,MichaelW, Sethi,Jigme, Steele,Chad, Duncan,StevenR]
通讯作者: Duncan,StevenR
Rituximab Therapy in Patients with IPF
Rituximab Therapy in Patients with IPF
Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF
  • 批准号:
    10218251
  • 项目类别:
  • 资助金额:
    $52.12万
  • 财政年份:
    2013
  • 负责人:
    STEVEN R DUNCAN
  • 依托单位:
Rituximab Therapy in Patients with IPF